Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tianjin TEDA Receives Approval For Biopharma Development Plan

This article was originally published in PharmAsia News

Executive Summary

Tianjin Economic-Technological Development Area has received approval for its biopharmaceutical industry plan, which aims to cultivate biopharmaceuticals as its key industry through a 10-year development plan. By 2015, the industry's output value will reach RMB 50 billion, accounting for 5 percent of TEDA's total value. With more than 200 pharmaceutical enterprises setting up bases, the development area seeks to be an influential drug R&D and manufacturing hub in Asia Pacific by participating in the international industry. TEDA will provide assurances and support for the biopharma sector in eight aspects, namely, system, space, funds, talent, policy, technology, services and resources. (Click here for more - Chinese language)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC071322

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel